Skip to main content
Caplight Logo









NovaGo Therapeutics

NovaGo Therapeutics

Private
SchlierenHealthcare & Life Scienceshttps://www.novagotherapeutics.com/

Last Round

Series B

Sep 2, 2026

Total Funding Raised

$41M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

NovaGo Therapeutics is a biotechnology company that develops human antibody therapeutics to promote nerve growth and regeneration for conditions like spinal cord injury and stroke.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologynerve regenerationantibody therapeuticsspinal cord injurybiologicsCNS repaircentral nervous systemclinical-stage biotechNogo-A inhibitionstroke treatmentdrug developmentregenerative medicineclinical trialsneuroscience startupbiotech spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NovaGo Therapeutics Comparables

Compare NovaGo Therapeutics with similar companies based on industry and business-model similarity.

NovaGo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ReNetX Bio
87%
CSPC Pharmaceutical Group Limited
77%
Axonis Therapeutics
77%

NovaGo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 2, 2026
Series AMar 4, 2019
GrantJan 1, 2015

Key People

Founding team and executive leadership

Roger Wetli

Chief Financial Officer

Executive Team

NovaGo Therapeutics Investors

Notable investors and investment history

NovaGo Therapeutics investors
InvestorRounds
Wings for Life FoundationSeries B
Wyss ZurichGrant
Pureos BioventuresSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    $30M round led by Neurimmune AG and Pureos Bioventures.

  • Jun 19, 2026

    Monthly visitors increased 89% MoM.

NovaGo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NovaGo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NovaGo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range10
Year Founded2015
Last FundingSep 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?